Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2262 | MVA-HPV Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001836 | Body Weight Changes NIH | 1.00 |
| D001835 | Body Weight NIH | 0.50 |
| D001068 | Feeding and Eating Disorders NIH | 0.33 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A Phase 1b/2 multi-centre study evaluating the safety, efficacy and immunogenicity of prime-boost vaccines ChAdOx1-HPV and MVA-HPV in women with HPV related low grade cervical lesions.
Description: Measure of adverse events, serious adverse events (SAEs), ≥Grade 3 study vaccine-related adverse events reported.
Measure: Incidence of adverse events to measure safety and reactogenicity Time: 3 months for the lead-in and 12 months for the main phaseDescription: Measurement of the highest multi-parameter index made of CD4+ magnitude, CD4+ avidity and CD8+ magnitude at peak timepoint
Measure: Determine the dose of ChAdOx1-HPV plus MVA-HPV vaccines for further development Time: 3 months for lead in phase and 12 months for main phaseDescription: The percentage of hrHPV infection clearance
Measure: Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on the clearance of high risk HPV infection Time: 12 months for main phase onlyDescription: The percentage of cervical lesions cleared as determined by colposcopy
Measure: Determine the effect of ChAdOx1-HPV plus MVA-HPV vaccines on cervical intraepithelial neoplasia (CIN) Time: 12 months for main phase onlyDescription: This will be assessed by measuring the individual phenotypic subsets of CD4+ and CD8+ T cells induced by vaccination
Measure: Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines Time: 3 months for lead in phase and 12 months for main phaseDescription: This will be assessed by measuring the innate immune response after vaccination compared to baseline
Measure: Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines Time: 3 months for lead in phase and 12 months for main phaseDescription: This will be assessed by measuring the T cell breadth of response to the components of the ChAdOx1-HPV plus MVA-HPV vaccines
Measure: Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines Time: 3 months for lead in phase and 12 months for main phaseDescription: Immune responses after prime and boost vaccinations in cytobrush samples compared to baseline
Measure: Assess the complex cellular immune response generated by ChAdOx1-HPV plus MVA-HPV vaccines Time: 3 months for lead in phase and 12 months for main phaseAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports